Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, March 18th.

Can-Fite BioPharma Price Performance

CANF opened at $1.60 on Friday. Can-Fite BioPharma has a one year low of $1.29 and a one year high of $4.69. The company’s 50 day simple moving average is $1.59 and its 200-day simple moving average is $1.87. The stock has a market capitalization of $5.66 million, a P/E ratio of -0.89 and a beta of 1.12.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.